Table 2.
Efficacy and tolerance of tranexamic acid (TA) in the 37 patients included
| Hereditary angioedema with C1-inhibitor deficiency | Hereditary angioedema with normal C1-inhibitor | Idiopathic non-histaminergic AE | Total | |
|---|---|---|---|---|
| TA efficacy | n = 12 patients | n = 6 patients | n = 19 patients | n = 37 |
| Attacks in the 6 months prior to TA: mean (range) | 14 (3, 48) | 16 (6, 50) | 15 (2, 48) | 15 (2, 50) |
| Of which severe attacks | 3† (1, 6) | 6‡ (3, 10) | 5‡ (0, 28) | 5 (0, 12) |
| Attacks in the 6 months after starting TA: mean (range) | 7 (0, 24) | 6 (4, 15) | 3 (0, 18) | 5 (0, 24) |
| Of which severe attacks | 1† (0, 3) | 2‡ (1, 3) | 1‡ (0, 5) | 1 (0, 5) |
| TA tolerance | ||||
| UE: number (patients) | 6 (4) | 3 (3) | 6 (4) | 15 (11) |
| Type (number) | Digestive (3), migraine (1), limb pains (1), weakness 1) | Digestive (3) | Digestive (4), dizziness (2) | |
| Reduction in dose due to UE | 2 | 1 | 1 | 4 |
| Discontinuation due to UE | 0 | 0 | 1 | 1 |
†Two cases with missing data; ‡one case with missing data. AE = angioedema; UE = undesirable event.